← Back to Search

Neurostimulation Device

Micro-Implantable Pulse Generator for Chronic Pain (COMFORT Trial)

N/A
Waitlist Available
Research Sponsored by Nalu Medical, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subject has been diagnosed with one or more of the conditions listed below in the low back, shoulder, knee, or foot (including ankle):Post-surgical/post-traumatic peripheral neuralgia including but not limited to pain due to peripheral nerve injury, post-surgical scar formation, nerve entrapment; Mononeuropathy, specified or unspecified or in diseases classified elsewhere; Other neuralgia or neuropathic pain; Osteoarthritic pain.
Subject should have a pain score of at least 6, in the target area of pain, as recorded on the BPI-Q5 (NRS) at screening.
Must not have
Subject has previously failed PNS or Spinal Cord Stimulation (SCS) or Dorsal Root Ganglion (DRG) therapy (trial or permanent implant)
Pain is completely absent at rest.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3, 6, 9, 12, 18, 24, 30 and 36 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether adding peripheral nerve stimulation to conventional medical management is more effective and safe than just using conventional medical management for chronic, intractable peripheral neuralgia that is of post-traumatic or post-surgical origin.

Who is the study for?
Adults aged 18-80 with chronic, intractable peripheral neuropathic pain for at least 6 months, not including the face. Pain must be mainly neuropathic from conditions like nerve injury or osteoarthritis. Participants need a pain score of at least 6 and stable medication use for 30 days. They can't have other active implants, recent successful pain treatments, uncontrolled mental health issues, allergies to device materials, certain medical conditions or be pregnant.
What is being tested?
The trial is testing the Nalu Neurostimulation System plus usual medical care against medical care alone for treating long-term peripheral neuralgia after trauma or surgery. It's a prospective study where participants are randomly assigned to either receive the new treatment or stick with standard care.
What are the potential side effects?
Possible side effects may include discomfort at the implant site, skin irritation from adhesives used in the device components, and potential infection risks associated with any implanted device.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have nerve or joint pain in my back, shoulder, knee, or foot due to surgery, injury, or arthritis.
Select...
My pain level in the target area is at least 6 out of 10.
Select...
I am between 18 and 80 years old.
Select...
My pain level in the target area is at least 6 out of 10.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have tried and not benefited from nerve or spinal cord stimulation therapies.
Select...
I do not experience pain when I am resting.
Select...
I have a diagnosed nerve pain condition like CRPS or Charcot-Marie-Tooth Disease.
Select...
My depression or psychiatric condition is not under control.
Select...
I have a bleeding or clotting disorder, or severe vascular disease that hasn't been treated.
Select...
I currently have an infection that affects my whole body.
Select...
I have cancer that has spread or shows signs of affecting my body in unusual ways.
Select...
I have diabetes with uncontrolled blood sugar and nerve damage.
Select...
I take 90 mg or more of pain medication equivalent to morphine daily.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3, 6, 9, 12, 18, 24, 30 and 36 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3, 6, 9, 12, 18, 24, 30 and 36 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Effectiveness: Responder rates between groups
Safety: Rate of serious and non-serious adverse events between groups
Secondary study objectives
Functional Outcomes: Change in ODI, BDI, EQ-5D, BPI from baseline
Responder Rates between groups at 12-months
Responder Rates between groups at 24-months
+3 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Conventional Medical ManagementExperimental Treatment1 Intervention
Control arm conventional medical management only
Group II: PNS Therapy plus Conventional Medical ManagementActive Control2 Interventions
peripheral nerve stimulator plus conventional medical management

Find a Location

Who is running the clinical trial?

Nalu Medical, Inc.Lead Sponsor
2 Previous Clinical Trials
295 Total Patients Enrolled
2 Trials studying Chronic Pain
295 Patients Enrolled for Chronic Pain
Patrick MartinStudy DirectorNalu Medical
2 Previous Clinical Trials
295 Total Patients Enrolled
2 Trials studying Chronic Pain
295 Patients Enrolled for Chronic Pain

Media Library

Nalu Neurostimulation System for PNS (Neurostimulation Device) Clinical Trial Eligibility Overview. Trial Name: NCT05287373 — N/A
Chronic Pain Research Study Groups: Conventional Medical Management, PNS Therapy plus Conventional Medical Management
Chronic Pain Clinical Trial 2023: Nalu Neurostimulation System for PNS Highlights & Side Effects. Trial Name: NCT05287373 — N/A
Nalu Neurostimulation System for PNS (Neurostimulation Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05287373 — N/A
Chronic Pain Patient Testimony for trial: Trial Name: NCT05287373 — N/A
~23 spots leftby Dec 2025